Investing.com - Biocept reported on Monday third quarter earnings that beat analysts' forecasts and revenue that topped expectations.
Biocept announced earnings per share of $-0.040 on revenue of $17.47M. Analysts polled by Investing.com anticipated EPS of $-0.160 on revenue of $9.14M.
Biocept shares are down 76% from the beginning of the year and are trading at $0.840 , down-from-52-week-high.
Biocept follows other major Healthcare sector earnings this month
Biocept's report follows an earnings beat by Eli Lilly on Tuesday, November 1, 2022, who reported EPS of $1.98 on revenue of $6.94B, compared to forecasts EPS of $1.91 on revenue of $6.91B.
AbbVie had beat expectations on Friday, October 28, 2022 with third quarter EPS of $3.66 on revenue of $14.81B, compared to forecast for EPS of $3.58 on revenue of $14.93B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar